Clinical trial
Vaccine To Prevent Cervical Intraepithelial Neoplasia or Cervical Cancer in…
NCT00128661 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00128661 |
|---|---|
| Title | Vaccine To Prevent Cervical Intraepithelial Neoplasia or Cervical Cancer in Younger Healthy Participants |
| Official title | A Double-Blind, Controlled, Randomized, Phase III Study of the Efficacy of an HPV16/18 VLP Vaccine in the Prevention of Advanced Cervical Intraepithelial Neoplasia (CIN2, CIN3, Adenocarcinoma In Situ [AIS] and Invasive Cervical Cancer) Associated With HPV 16 or HPV 18 Cervical Infection in Healthy… |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Cervical Cancer, Precancerous Condition |
| Intervention type | Biological |
| Interventions | human papillomavirus 16/18 L1 virus-like particle/AS04 vaccine, hepatitis A inactivated virus vaccine |
| Enrollment | 7,466 |
| Start date | Jun 30, 2004 |
| Primary completion | Dec 31, 2010 |
| Completion | Dec 31, 2010 |
| First posted | Aug 10, 2005 |
| Last update posted | Mar 8, 2019 |
| Countries | Costa Rica |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: